LATITUDE, a phase 3 double-blind, randomized trial of androgen deprivation therapy (ADT) with abiraterone acetate (AA) plus prednisone (P) or placebos (PBOs) in patients (pts) with newly diagnosed high-risk metastatic hormone-naive prostate cancer (mHNPC)

Author
Fizazi, K.
Chi, K.
Feyerabend, S.
Matsubara, N.
Rodriguez Antolin, A.
Alekseev, B.
Ozguroglu, M.
Ye, D.
Protheroe, A.
De Porre, P.
Kheoh, T.
Park, Y. C.
Todd, M.
Tran, N.
Fein, L.
Metadata
Show full item record
URI
http://hdl.handle.net/20.500.12627/145899
Collections